DiaSorin (DIA) investor relations material

Executive summary

• Q3 revenue was €308.0m, up 8% CER and 10% at current exchange rates; 9M revenue was €909.6m, up 3% CER and 1% reported.

• Q3 adjusted EBITDA was €103m, with a 34% CER margin; FY26 revenue and adjusted EBITDA margin guidance was reaffirmed.

Financial highlights

• Q3 reported EBIT was €67m, up 20%, and reported net profit was €42.2m, up 10%; adjusted net profit was €53.6m, up 6%.

• 9M reported EBIT was €192m, down 1%, and reported net profit was €126m, down 8%; adjusted net profit was €159m, down 10%.

• 9M adjusted gross profit was €588m, up 1% CER, with a 65% margin; Q3 adjusted gross profit was €198m, with a 64% margin.

• 9M adjusted EBIT was €228m, down 2% CER, with a 25% margin; Q3 adjusted EBIT was €79.6m, with a 26% margin.

• 9M adjusted net financial expenses rose to €14m from €1m, mainly reflecting lower cash investment income, buyback costs and higher borrowing expenses.

Outlook and guidance

• FY26 guidance was reaffirmed at 5%–6% revenue growth and a 32%–33% adjusted EBITDA margin, based on 2025 CER.

• Guidance assumes a respiratory season broadly in line with 2025; a similar season would imply the lower end of the revenue-growth range.

• Molecular growth is expected to benefit from LIAISON PLEX menu expansion and LIAISON NES execution; Immunodiagnostics from specialty tests and hospital strategy, partly offset by China weakness.

• A €0.01 EUR/USD move over 12 months affects FY revenue by €6m–€8m and EBITDA by €2m–€3m; estimated FY FX impact is €15m at USD/EUR 1.11–1.12 or €10m at 1.10.